Market research
XAIR Beyond Air Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5M
- P/E ratio
- 0.02
- Analyst target
- 30
- Dividend yield
- Not available
- Beta
- 0.15
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US08862L3015
- Market cap
- 5M
- P/E ratio
- 0.02
- Analyst target
- 30
- Dividend yield
- Not available
- Beta
- 0.15
About
About Beyond Air Inc
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the XAIR discussion.
5 years, 4 months ago
Beyond Air, Inc is currently in a long term uptrend where the price is trading 6.3% above its 200 day moving average.
From a valuation standpoint, the stock is 87.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 173.0.
Beyond Air, Inc's total revenue sank by 52.7% to $149K since the same quarter in the previous year.
Its net income has increased by 99.9% to $-6K since the same quarter in the previous year.
Finally, its free cash flow fell by 213.4% to $-15M since the same quarter in the previous year.
Based on the above factors, Beyond Air, Inc gets an overall score of 3/5.